Status:
RECRUITING
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
Lead Sponsor:
University Children's Hospital, Zurich
Conditions:
Hematological Malignancies
Eligibility:
All Genders
Up to 40 years
Brief Summary
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at singl...
Detailed Description
This observational study offers a platform to assess the drug sensitivity of primary leukemia cells ex vivo. The cancer cells are co-cultured in multi-well plates with supporting mesenchymal stroma ce...
Eligibility Criteria
Inclusion
- Pediatric and adult patients below the age of 40 years
- Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma
- Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research
- Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.
Exclusion
- Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research
Key Trial Info
Start Date :
January 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2031
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06550102
Start Date
January 4 2022
End Date
December 31 2031
Last Update
August 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Children's Hospital Zurich
Zurich, Canton of Zurich, Switzerland, 8032